MDx Firm QuanDx Closes Series B Financing | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuanDx announced on Thursday the closing of its Series B financing round raising $1.25 million.

Proceeds will go toward further development of its platform technology and its commercial program in oncology, genetic diseases, and infectious diseases. The Menlo Park, Calif.-based company did not disclose the names of the investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.